FMC1-LUC7L2: A Drug Target / Disease Biomarker (G100996928)

Target Name: FMC1-LUC7L2

NCBI ID: G100996928

FMC1-LUC7L2

FMC1-LUC7L2: A Drug Target / Disease Biomarker

FMC1-LUC7L2 is a protein that is expressed in various tissues of the body, including the brain, pancreas, and gastrointestinal tract. It is a member of the Leucine-rich repeat (LRR) family of proteins, which are characterized by the presence of a specific repeat sequence in the N-terminus of the protein that is composed of leucine amino acids.

FMC1-LUC7L2 is also known as Fc-LUC7L2, or FMLN-L2, and it is expressed in a variety of tissues, including the brain, pancreas, and gastrointestinal tract. It is a type of transmembrane protein, which means that it spans the cell membrane and is involved in the function of the cell as a whole.

One of the unique features of FMC1-LUC7L2 is its expression pattern. It is primarily expressed in the brain and pancreas, and it is also expressed in the gastrointestinal tract, where it is involved in the function of the gut-brain axis. This suggests that FMC1-LUC7L2 may be involved in the regulation of a variety of physiological processes that are important for the health and function of the gut-brain axis.

In addition to its expression pattern, FMC1-LUC7L2 has also been shown to play a role in several cellular processes that are important for the development and progression of several diseases, including cancer. For example, studies have shown that FMC1-LUC7L2 is involved in the regulation of cell adhesion, which is the process by which cells stick together and form tissues.

FMC1-LUC7L2 has also been shown to be involved in the regulation of several signaling pathways that are important for the development and progression of cancer. For example, studies have shown that FMC1-LUC7L2 is involved in the regulation of the PI3K/Akt signaling pathway, which is a pathway that is important for the development and progression of many types of cancer.

In addition to its involvement in cancer, FMC1-LUC7L2 has also been shown to be involved in the regulation of several other cellular processes that are important for the health and function of the body. For example, it is involved in the regulation of cell migration, which is the process by which cells move from one location to another in the body, and it is also involved in the regulation of cell survival, which is the process by which cells live and die.

Despite its involvement in a wide range of cellular processes, FMC1-LUC7L2 is not well understood, and there is much that is still to be learned about its function. One of the challenges in studying FMC1-LUC7L2 is its complex expression pattern and its involvement in multiple cellular processes, which can make it difficult to identify its true function.

In conclusion, FMC1-LUC7L2 is a protein that is expressed in various tissues of the body and is involved in a wide range of cellular processes that are important for the health and function of the body. While more research is needed to fully understand its function, studies have shown that FMC1-LUC7L2 is involved in the regulation of several important cellular processes and is a potential drug target or biomarker for a variety of diseases.

Protein Name: FMC1-LUC7L2 Readthrough

Functions: Plays a role in the assembly/stability of the mitochondrial membrane ATP synthase (F(1)F(0) ATP synthase or Complex V) (PubMed:28719601)

The "FMC1-LUC7L2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FMC1-LUC7L2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets